No photo of Rimas Vincas Lukas

View Scopus Profile

Rimas Vincas Lukas

  • 570 Citations
20052023
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research Interests

Dr. Lukas, sub-specializing in neuro-oncology, is interested in the care of patients with primary brain tumors and spinal cord tumors as well as central nervous system (CNS) metastases. Dr. Lukas's research centers on clinical trials in neuro-oncology. Additionally, he has a strong interest in medical education in the U.S. and internationally and conducts research in neuroscience medical education.

Training Experience

2003Internship, Cook County Hospital, Chicago
2006Residency, University of Chicago Hospitals
2008Fellowship, University of Chicago

Education/Academic qualification

MD, Rush University

… → 2002

Research interests

  • Brain Cancer / Nervous System Cancer
  • Medical Education
  • Neuro-Oncology
  • Spinal Cord Tumors
  • Spinal Oncology

Fingerprint Dive into the research topics where Rimas Vincas Lukas is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 12 Similar Profiles
Glioblastoma Medicine & Life Sciences
Neurology Medicine & Life Sciences
Neoplasm Metastasis Medicine & Life Sciences
Glioma Medicine & Life Sciences
Medical Students Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Central Nervous System Medicine & Life Sciences
Brain Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2018 2023

Relationship between Psychological Distress an the Efficacy of Immunotherapy in Patients with Glioblastoma

Lukas, R. V. & Wainwright, D. A.

BrainUp Inc.

7/1/19 → 6/30/21

Project: Research project

Prot #ATI001-204: A Phase II Study of Ad-RTS-hIL-12 + Veledimex in Combination with Cemiplimab-rwlc (Libtayo®) in Subjects with Recurrent or Progressive Glioblastoma

Lukas, R. V.

ZIOPHARM Oncology, Inc.

6/5/19 → 6/5/22

Project: Research project

NU C18C01 - A Phase I Study of Safety and Tolerability of Acetazolomide with Temozolomide in Adults with Newly Diagnosed MGMT Promotermethylated Malignant Glioma

Lukas, R. V.

University of Chicago, BrainUp Inc.

12/1/18 → 12/31/20

Project: Research project

SPORE for Translational Approaches to Brain Cancer

Ahmed, A. U., Balyasnikova, I. V., Bartom, E. T., Brat, D. J., Chandler, J. P., Cheng, S., Horbinski, C. M., Hu, B., James, C. D., Kumthekar, P. U., Leikin, R. G., Lesniak, M. S., Liu, B. P., Lukas, R. V., Mirkin, C. A., Platanias, L. C., Sachdev, S., Scholtens, D. M., Stegh, A. H., Stupp, R. & Wainwright, D. A.

National Cancer Institute

8/17/18 → 7/31/23

Project: Research project

Brain Neoplasms
Glioblastoma
Therapeutics
Neoplasms
Survival

Research Output 2005 2019

1 Citation (Scopus)

Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study

Gadgeel, S. M., Lukas, R. V., Goldschmidt, J., Conkling, P., Park, K., Cortinovis, D., de Marinis, F., Rittmeyer, A., Patel, J. D., von Pawel, J., O'Hear, C., Lai, C., Hu, S., Ballinger, M., Sandler, A., Gandhi, M. & Fehrenbacher, L., Feb 1 2019, In : Lung Cancer. 128, p. 105-112 8 p.

Research output: Contribution to journal › Article

docetaxel
Non-Small Cell Lung Carcinoma
Neoplasm Metastasis
Brain
Nervous System

Author Correction: Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma (Nature Medicine, (2019), 25, 3, (462-469), 10.1038/s41591-019-0349-y)

Zhao, J., Chen, A. X., Gartrell, R. D., Silverman, A. M., Aparicio, L., Chu, T., Bordbar, D., Shan, D., Samanamud, J., Mahajan, A., Filip, I., Orenbuch, R., Goetz, M., Yamaguchi, J. T., Cloney, M., Horbinski, C. M., Lukas, R. V., Raizer, J., Rae, A. I., Yuan, J. & 7 others, Canoll, P., Bruce, J. N., Saenger, Y. M., Sims, P., Iwamoto, F. M., Sonabend Worthalter, A. M. & Rabadan, R., Jun 1 2019, In : Nature Medicine. 25, 6, 1 p.

Research output: Contribution to journal › Comment/debate

Open Access
Glioblastoma
Immunotherapy
Medicine

Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017)

Zhai, L., Ladomersky, E., Lauing, K. L., Wu, M., Scholtens, D. M., Savoor, R., Zhang, B., Wu, J. D., Horbinski, C. M., Lukas, R. V., Binder, D. C. & Wainwright, D. A., Mar 4 2019, In : OncoImmunology. 8, 3, 1548242.

Research output: Contribution to journal › Comment/debate

Glioblastoma
Biomarkers
Computational Biology
Gene Expression

Commentary: braf v600 mutation and braf kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases: a multicenter retrospective study

Lukas, R. V., Apr 1 2019, In : Clinical Neurosurgery. 84, 4, p. 881-882 2 p.

Research output: Contribution to journal › Comment/debate

Open Access
Radiosurgery
Multicenter Studies
Melanoma
Phosphotransferases
Retrospective Studies

Comments

Lukas, R. V., Mar 1 2019, In : Clinical neurosurgery. 84, 3, 1 p.

Research output: Contribution to journal › Comment/debate